n-Lorem Foundation Partners with Hongene Biotech Corporation to Support the Discovery of Personalized ASO Medicines for Nano-rare Patients [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Yahoo! Finance
n-Lorem's efforts to discover and provide personalized experimental antisense oligonucleotide (ASO) medicines to nano-rare disease patients (1 to 30 patients worldwide) for free, for life. As part of its commitment to n-Lorem and nano-rare patients, Hongene will provide amidites, compounds essential to developing ASO medicines, to n-Lorem to offset the costs of developing ASO medicines for up to 20 nano-rare patients. "In many cases, nano-rare patients will succumb to their disease without ever having hope of a treatment that will halt their progressive diseases. At n-Lorem, we can and are changing this for nano-rare patients today. Our approach enables us to discover and develop an individualized ASO medicine that targets a nano-rare patient's unique mutation, and we do this for free, for life," said Stanley T. Crooke, M.D., Ph.D., Chairman, Founder, and CEO, n-Lorem Foundation. "The need from the nano-rare community is substantial and we cannot do this alone. Thanks to the generos
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release [Yahoo! Finance]Yahoo! Finance
- WAYLIVRA (Volanesorsen) for Lipodystrophy Research Report 2024: Market Size, Forecasts, and Emerging Insight 2019-2032 - Focus on United States, Germany, France, Italy, Spain, United Kingdom, & Japan [Yahoo! Finance]Yahoo! Finance
- Ionis Publishes 2023 Corporate Responsibility Report [Yahoo! Finance]Yahoo! Finance
- Ionis Publishes 2023 Corporate Responsibility ReportPR Newswire
- Ionis to hold first quarter 2024 financial results webcastPR Newswire
IONS
Earnings
- 2/21/24 - Beat
IONS
Sec Filings
- 5/3/24 - Form 144
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- IONS's page on the SEC website